Similar articles

• Comparative study of several hypolipidemic agents related to clofibrate.

  Beaumont V, Buxtorf JC, Jacotot B, Beaumont JL. Beaumont V, et al. Atherosclerosis. 1974 Sep-Oct;20(2):141-53. doi: 10.1016/0021-9150(74)90001-x. Atherosclerosis. 1974. PMID: 4369878 Clinical Trial. No abstract available.
• Clinical evaluation of MK-185: a new hypolipidemic drug.

  Sirtori C, Hurwitz A, Sabih K, Azarnoff D. Sirtori C, et al. Lipids. 1972 Feb;7(2):96-9. doi: 10.1007/BF02532594. Lipids. 1972. PMID: 4551950 Clinical Trial. No abstract available.
• A double-blind comparison of the hypolipidemic and hypouricemic action of halofenate and clofibrate in patients with hyperlipoproteinemia (types III, IV and V).

  Neuman J, de Neuman MP, Talmasky S, Pesce R, Valero E, Martiarena JL. Neuman J, et al. J Cardiovasc Surg (Torino). 1973;Spec No:532-7. J Cardiovasc Surg (Torino). 1973. PMID: 4377715 Clinical Trial. No abstract available.
• Dietary and drug treatment of primary hyperlipoproteinemia.

  [No authors listed] [No authors listed] Ann Intern Med. 1972 Aug;77(2):267-94. doi: 10.7326/0003-4819-77-2-267. Ann Intern Med. 1972. PMID: 4345081 Review. No abstract available.
• Type IV hyperlipoproteinaemia.

  Kwiterovich PO Jr, Margolis S. Kwiterovich PO Jr, et al. Clin Endocrinol Metab. 1973 Mar;2(1):41-71. doi: 10.1016/s0300-595x(73)80026-x. Clin Endocrinol Metab. 1973. PMID: 4359117 Review. No abstract available.